Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Compare Mammostrat score clinical response rates to chemotherapy
研究概览
简要总结
Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to determine whom would benefit from chemotherapy prior to surgery. Also could be used as a clinical marker to identify patients with breast cancer who do not benefit from some preoperative chemotherapies.
详细描述
The purpose of this phase II study is to find out if the test, Mammostrat® can be used as a predictor or outcome tool to determine who will best benefit from chemotherapy prior to surgery. This can be used to determine if Mammostrat assay may be used as a clinical marker to identify a subset of women with breast cancer who do not benefit from preoperative chemotherapy, either taxane/taxane-like (T) chemo agents or anthracycline-based chemotherapy and cyclophosphamide (AC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologic confirmation of invasive breast carcinoma.
- •Patients must have intact primary tumor.
- •≥18 years of age.
- •Patients with bilateral breast cancer are eligible.
- •Patients with second primary breast cancers are eligible.
- •The primary breast tumor must be ≥ 2 cm by physical exam or imaging.
- •The tumor must have been determined to be HER2-negative as follows:
- •Fluorescent in situ hybridization (FISH)-negative (defined by ratio of HER2 to CEP17 must be < 2.2)
- •Immunohistochemistry (IHC) 0-1+; or
- •IHC 2+ and FISH-negative
- •ECOG PS of 0, 1, or
- •Negative serum pregnancy test ≤7 days of treatment initiation and a serum or urine pregnancy test must be repeated ≤ 3 days prior to starting treatment for women of childbearing potential (WOCBP). For WOCBP, adequate contraception must be used throughout the study. For this study, acceptable methods of contraception include a reliable intrauterine device or a spermicide in combination with a barrier method. Women who are already on hormonal forms of birth control may continue that treatment but must also use a barrier method.
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
- •Patient must be willing to undergo breast biopsies as required by the study protocol.
- •Sufficient tissue must be available from the diagnostic core biopsies. If not, patients must undergo additional biopsies to perform Mammostrat.
排除标准
- •Patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer and non-invasive cervical cancer.
- •Prior treatment with any investigational drug within the preceding 4 weeks.
- •Evidence of New York Heart Association class III or greater cardiac disease.
- •History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months.
- •Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart Failure or major surgery) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •Pregnant or nursing women.
- •Known allergic reaction to Cremophor or any of the chemo agents on this trial.
研究组 & 干预措施
taxane-based chemotherapy
physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
干预措施: taxane-based chemotherapy (Drug)
anthacycline based chemotherapy
Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
干预措施: Anthracycline based chemotherapy (Drug)
结局指标
主要结局
Compare Mammostrat score clinical response rates to chemotherapy
时间窗: 2 years
The percentage of patients undergoing chemotherapy who have Mammostrat low risk scores will be calculated
次要结局
- pathological complete response rate compare to predictors(2 years)
研究者
Jenny C. Chang, MD
Methodist Cancer Center Director (Rodriguez no longer at MCC)
The Methodist Hospital Research Institute